Emerging Neuroscience company, Cybin appoints globally experienced, public company CEO to the helm


Subscribe to receive industry-focused thought leadership and insights, delivered right to your inbox Subscribe

Bedford would like to congratulate Doug Drysdale on his appointment as Chief Executive Officer (“CEO”) of Cybin.

Drysdale brings 30+ years of experience in the health care sector as both a global business development leader and Chief Executive officer of private and public Life Sciences companies inclusive of closing significant M&A deals and raising capital.

Earlier in his career, Doug served as Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates, including over 25 banks, to fund its growth. Actavis was sold to Watson Pharmaceuticals in 2012 for €4.25 billion.

“With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Paul Glavine Cybin’s Co-founder and Chief Operating Officer. “We believe that his extensive health care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances, and expand our international presence. We believe his strong leadership experience will help focus Cybin during our initial path to profitability.”

The entire press release can be found here.

Darren Raycroft

Darren Raycroft

Partner and Managing Director

Email: draycroft@bedfordgroup.com
Tel: 416-963-9000 x. 234

Howard Pezim

Howard Pezim

Co-Founder and Managing Director

Email: howardp@bedfordgroup.com
Tel: 416-963-9000, ext.223

Recently completed Life Sciences and Healthcare Searches